Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997363 | 0.91 | SRD5A2 (0.63) | SMN1; SMN2SRD5A2CA1CA2KDM4E | |
| SCHEMBL4557296 | 0.88 | SYK (0.53) | SMN1; SMN2SRD5A2KDM4EMEN1KMT2A | |
| SCHEMBL9652658 | 0.87 | SRD5A2 (0.57) | SMN1; SMN2SRD5A2RXRAPTPN11RAB9A | |
| SCHEMBL6892386 | 0.84 | SRD5A2 (0.53) | SMN1; SMN2SRD5A2RXRAPTPN11TP53 | |
| SCHEMBL6059390 | 0.84 | CA1 (0.63) | SMN1; SMN2CA1CA2KDM4ERXRA | |
| SCHEMBL6884735 | 0.83 | RXRA (0.51) | SRD5A2CA1CA2RXRAPTPN11 | |
| SCHEMBL2635961 | 0.82 | BCL2 (0.50) | SMN1; SMN2SRD5A2KDM4ERXRAKMT2A | |
| SCHEMBL4557299 | 0.82 | SRD5A2 (0.50) | SMN1; SMN2SRD5A2KDM4EMEN1KMT2A | |
| SCHEMBL6536178 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2CA1CA2KDM4ERXRA | |
| SCHEMBL5024584 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2CA1CA2KDM4ERXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | SALTIGO GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-1924539-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | Saltigo GmbH (DE) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007031511-A1 | NICKEL OR IRON CATALYSED CARBON-CARBON COUPLING REACTION OF ARYLENES, ALKENES AND ALKINES | SALTIGO GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | SMN1; SMN2 4536/4885SRD5A2 2534/4885CA1 4653/4885 |
| US-20100184977-A1 | Nickel or Iron Catalysed Carbon-Carbon Coupling Reaction of Arylenes, Alkenes and Alkines | MON2, ZRANB2, GRIA2 | SMN1; SMN2 3249/4885SRD5A2 1062/4885CA1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.